



## **Elekta announces intention to acquire RTA, a leading distributor in Poland**

STOCKHOLM, August 25, 2014 – Elekta today announced its intention to acquire RTA, a leading distributor from Poland specializing in cutting-edge radiation therapy technologies. The acquisition will significantly strengthen Elekta’s position in the Polish cancer care market.

With the incidence of cancer in Poland expected to increase by almost 19 percent between 2012 and 2025\*, the need for treatment equipment will escalate accordingly. Today Poland has just over 100 linear accelerators (linacs) used to deliver radiation therapy to treat cancer, but according to E Rosenblatt MD, et al\*\*, the optimal number of linacs for country is almost 200.

“The acquisition of RTA would optimally position Elekta to capture the opportunities for the growth of radiation therapy in Poland,” says Niklas Savander, President and CEO of Elekta. “Developing the multi-year relationship we have with RTA into the establishment of an Elekta office, is an important step on our path to higher growth.”

Acquiring RTA is expected to add approximately 0.3 percent to Elekta’s revenues on an annual basis. Once approved, the transaction is expected to be EPS accretive on an annual basis. Once the agreement has been signed and approved, a three-year earn out component between seller and Elekta is expected.

Closing will take place in January 2015. RTA will then change its name to Elekta and will be a wholly-owned subsidiary.

\* [GLOBOCAN 2012](#)

\*\* *Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database, [Lancet Oncol 2006; 7: 584–95](#)*

###

### **For further information, please contact:**

Gert van Santen, Group Vice President Corporate Communications, Elekta AB  
Tel: +31 653 561 242, e-mail: [gert.vansanten@elekta.com](mailto:gert.vansanten@elekta.com)  
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB  
Tel: +46 702 100 451, e-mail: [johan.andersson@elekta.com](mailto:johan.andersson@elekta.com)  
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on August 25, 2014.

### **About Elekta**

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.



Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, ElektA aims to improve, prolong and even save patient lives.

Today, ElektA solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. ElektA employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: [www.elektA.com](http://www.elektA.com).